AI Article Synopsis
- A 25-year-old patient became pregnant while receiving ustekinumab treatment, and the medication was stopped as soon as the pregnancy was confirmed.
- The pregnancy proceeded without complications, and the child is now 14 months old and developing well.
- Among four documented cases of pregnancy during ustekinumab therapy, there was one reported miscarriage.
Article Abstract
We report the case of a 25-year-old patient who became pregnant during ustekinumab therapy. Treatment was suspended immediately after pregnancy had been confirmed. The patient had an uneventful pregnancy and her child is currently 14 months old, with adequate development to her age. Four reports of pregnancy during ustekinumab treatment have been reported and one resulted in miscarriage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000380880 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.
Int Arch Allergy Immunol
December 2024
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the safety of various biologics used for psoriasis during pregnancy, highlighting that data on risks is lacking outside of TNF-α inhibitors.
- Using the WHO global pharmacovigilance database, researchers analyzed over 6,500 reports of pregnancy-related adverse outcomes and compared them among different biologics.
- The findings indicate that most biologics have a lower frequency of adverse pregnancy-related outcomes compared to TNF-α inhibitors, except for brodalumab, while risankizumab showed a higher incidence of abortion and stillbirth.
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis.
J Pharm Health Care Sci
October 2024
Department of Pharmacy, Fukuoka University Chikushi Hospital, 1-1-1, Zokumyoin, Chikushino-Shi, Fukuoka, 818-8502, Japan.
Background: The therapeutic landscape for ulcerative colitis (UC) has recently broadened to include anti-TNFα, anti-integrin, and anti-IL-12/23p40 antibody agents. These biological agents are tailored to individual patient profiles. However, some patients cease biological treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!